Galecto
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Galecto and other ETFs, options, and stocks.About GLTO
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2.
CEOHans Thalsgård Schambye
CEOHans Thalsgård Schambye
Employees5
Employees5
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded2011
Founded2011
Employees5
Employees5
GLTO Key Statistics
Market cap7.88M
Market cap7.88M
Price-Earnings ratio-0.45
Price-Earnings ratio-0.45
Dividend yield—
Dividend yield—
Average volume80.17K
Average volume80.17K
High today$6.10
High today$6.10
Low today$5.80
Low today$5.80
Open price$5.80
Open price$5.80
Volume21.66K
Volume21.66K
52 Week high$31.70
52 Week high$31.70
52 Week low$2.01
52 Week low$2.01
Stock Snapshot
The current Galecto(GLTO) stock price is $5.85, with a market capitalization of 7.88M. The stock trades at a price-to-earnings (P/E) ratio of -0.45.
During the trading session on 2025-11-05, Galecto(GLTO) shares reached a daily high of $6.10 and a low of $5.80. At a current price of $5.85, the stock is +0.9% higher than the low and still -4.1% under the high.
Trading volume for Galecto(GLTO) stock has reached 21.66K, versus its average volume of 80.17K.
The stock's 52-week range extends from a low of $2.01 to a high of $31.70.
The stock's 52-week range extends from a low of $2.01 to a high of $31.70.
People also own
Based on the portfolios of people who own GLTO. This list is generated using Robinhood data, and it’s not a recommendation.